SGLT2 Inhibitors in Type 2 Diabetes Management

Introduction to SGLT2 Inhibitors

The American College of Cardiology recommends starting empagliflozin at 10 mg once daily or canagliflozin at 100 mg once daily for cardiovascular and renal protection, with the lowest dose providing full cardioprotective benefit 1, 2

The American College of Cardiology suggests that empagliflozin and canagliflozin should be initiated at their lowest doses, with empagliflozin at 10 mg orally once daily and canagliflozin at 100 mg orally once daily, for patients with type 2 diabetes 1
Dapagliflozin is recommended at a standard dose of 10 mg orally once daily, with no titration needed, for type 2 diabetes management 3, 4

The American College of Cardiology advises assessing eGFR before initiating any SGLT2 inhibitor, with empagliflozin not recommended if eGFR is below 45 mL/min/1.73 m², while canagliflozin and dapagliflozin can be initiated down to eGFR 30 mL/min/1.73 m² for cardiovascular and renal protection 1, 3, 4

SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalization, and progression of kidney disease, independent of glucose-lowering effects, making them beneficial for patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease 1, 3, 4
Empagliflozin reduces cardiovascular death by 38% (HR 0.62, 95% CI 0.49-0.77) and all-cause mortality by 32% (HR 0.68, 95% CI 0.57-0.82) 1

SGLT2 inhibitors reduce the risk of end-stage kidney disease, doubling of serum creatinine, and renal death, with canagliflozin having FDA approval for reducing the risk of end-stage kidney disease in diabetic nephropathy with albuminuria 3, 4

The American College of Cardiology recommends initiating an SGLT2 inhibitor with proven cardiovascular benefit in all patients with type 2 diabetes and established atherosclerotic cardiovascular disease, regardless of baseline HbA1c or current glucose control 1, 3, 2

Assess volume status before initiating SGLT2 inhibitors and consider reducing loop diuretic dose by 50% in patients on high-dose diuretics to prevent symptomatic hypotension 3, 5, 6
Counsel patients about the increased risk of genital yeast infections and the importance of proper genital hygiene 4, 5, 6
Warn patients about the risk of euglycemic diabetic ketoacidosis, especially during acute illness or surgery, and advise temporary discontinuation of SGLT2 inhibitors in such situations 3, 4, 5
Reduce insulin dose by approximately 20% and reduce or discontinue sulfonylureas when initiating SGLT2 inhibitors to prevent hypoglycemia 3, 5, 6

History of serious hypersensitivity reaction to the specific SGLT2 inhibitor, severe renal impairment, end-stage renal disease, or dialysis, and type 1 diabetes mellitus are contraindications for SGLT2 inhibitor use 5, 6